Founder/CEO Di Pietro Health Fort Lauderdale, Florida, United States
Disclosure(s):
Robert J. Chilton, DO, MACOI: No financial relationships to disclose
Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 AHA/ACC Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 73(24), e285–e350. https://doi.org/10.1016/j.jacc.2018.11.003
Mach, F., Baigent, C., Catapano, A. L., et al. (2019). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455
Bhatt, D. L., Steg, P. G., Miller, M., et al. (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine, 380(1), 11–22. https://doi.org/10.1056/NEJMoa1812792
Learning Objectives:
Understand the Classification and Risk Factors of Hyperlipidemia: Learners will be able to distinguish between primary and secondary causes of hyperlipidemia and identify key.
Learners will gain the ability to use the ASCVD risk calculator and lipid panel results to stratify cardiovascular risk and guide treatment decisions in adults aged 20–75.
Learners will be able to compare the indications, mechanisms, and side effects of statins, ezetimibe, PCSK9 inhibitors, fibrates, and other lipid-lowering agents for individualized patient care.
